Bioconjug Chem. 2019 May 15;30(5):1415-1424. doi: 10.1021/acs.bioconjchem.9b00160. Epub 2019 Apr 12.
Ovarian cancer is commonly diagnosed only after it has metastasized to the abdominal cavity (stage III). While the current standard of care of intraperitoneal (IP) administration of cisplatin and paclitaxel (PTX) combination chemotherapy has benefit, patient 5-year survival rates are low and have not significantly improved in the past decade. The ability to target chemotherapy selectively to ovarian tumors while sparing normal tissue would improve efficacy and decrease toxicities. We have previously shown that cisplatin-loaded nanoparticles (NPs) loaded within neural stem cells (NSCs) are selectively delivered to ovarian tumors in the abdominal cavity following IP injection, with no evidence of localization to normal tissue. Here we extended the capabilities of this system to also include PTX delivery. NPs that will be loaded into NSCs must contain a high amount of drug by weight but constrain the release of the drug such that the NSCs are viable after loading and can successfully migrate to tumors. We developed silica coated PTX nanocrystals (Si[PTX-NC]) meeting these requirements. Si[PTX-NC] were more effective than uncoated PTX-NC or Abraxane for loading NSCs with PTX. NSCs loaded with Si[PTX-NC] maintained their migratory ability and, for low dose PTX, were more effective than free PTX-NC or Si[PTX-NC] at killing ovarian tumors in vivo. This work demonstrates that NSC/NP delivery is a platform technology amenable to delivering different therapeutics and enables the pursuit of NSC/NP targeted delivery of the entire preferred chemotherapy regimen for ovarian cancer. It also describes efficient silica coating chemistry for PTX nanocrystals that may have applications beyond our focus on NSC transport.
卵巢癌通常在转移到腹腔(III 期)后才被诊断出来。虽然目前腹腔内顺铂和紫杉醇(PTX)联合化疗的标准治疗方法有效,但患者的 5 年生存率仍然较低,在过去十年中没有显著提高。能够将化疗药物选择性靶向卵巢肿瘤,同时保护正常组织,将提高疗效,降低毒性。我们之前已经表明,负载顺铂的纳米颗粒(NPs)负载在神经干细胞(NSCs)内,腹腔内注射后可选择性递送到腹腔内的卵巢肿瘤,而没有正常组织定位的证据。在这里,我们扩展了该系统的功能,还包括 PTX 的递送。要装入 NSCs 的 NPs 必须按重量包含大量药物,但要限制药物的释放,以使装入后 NSCs 仍具有活力,并能成功迁移到肿瘤。我们开发了满足这些要求的硅涂层紫杉醇纳米晶体(Si[PTX-NC])。Si[PTX-NC]比未涂层的 PTX-NC 或 Abraxane 更有效地将 PTX 装入 NSCs。负载 Si[PTX-NC]的 NSCs 保持其迁移能力,对于低剂量的 PTX,与游离的 PTX-NC 或 Si[PTX-NC]相比,在体内杀死卵巢肿瘤的效果更好。这项工作表明,NSC/NP 递送是一种平台技术,适用于递送不同的治疗药物,并能够追求 NSC/NP 靶向递送卵巢癌的整个首选化疗方案。它还描述了用于 PTX 纳米晶体的高效硅涂层化学,除了我们关注的 NSC 运输之外,它可能还有其他应用。